Inhibikase Therapeutics, Inc. Common Stock IKT
Analyst Ratings
- Consensus
- Buy — 5 Buy · 0 Hold · 0 Sell (5 analysts)
- Avg. Price Target
- $5.40 (+142.7% upside)
Key Stats
- Today's Range
- $2.22 – $2.32
- 50-Day Range
- $1.93 – $2.61
- 52-Week Range
- $1.33 – $2.61
- Volume
- 146K shs
- Average Volume
- 490K shs
- Market Cap
- $320.93 million
- P/E Ratio
- —
- Dividend Yield
- —
Valuation
- P/E Ratio
- —
- Price / Book
- 2.09
- Price / Sales
- 86.39
Short Interest
- Short Interest
- 0.02%
- Days to Cover
- 1.00
Financials (TTM)
- Revenue
- $3.72 million
- Net Income
- $-60,637,002
- Net Margin
- -1632.18%
- Return on Equity
- -39.55%
- Debt-to-Equity
- —
About Inhibikase Therapeutics, Inc. Common Stock
Inhibikase Therapeutics Inc a clinical-stage pharmaceutical company developing therapeutics to modify the course of cardiopulmonary diseases, namely, Pulmonary Arterial Hypertension (PAH), in which aberrant signaling through type III receptor tyrosine kinases, including platelet derived growth factor receptors and a stem cell factor receptor, known as c-Kit, has been implicated. Its product candidate is IKT-001, a prodrug of imatinib mesylate (imatinib), for PAH which is an orphan indication. The company has developed its own portfolio of protein kinase inhibitors to treat bacterial and viral infections, including viral infections in the brain. It has one reporting segment, which is the business of developing protein kinase inhibitor therapeutics.
Related Stocks
Compare head-to-head: IKT vs AMGN·IKT vs MRNA·IKT vs HALO·IKT vs TWST
Price and fundamental data are delayed and provided for informational purposes only. Not investment advice. See our disclaimer.